Ovagen

Research Overview

Ovagen serves as a research tool for investigating liver and digestive-system bioregulation in laboratory settings. This peptide bioregulator belongs to the class of Khavinson short peptides, a family of synthetic regulatory peptides originally developed through research on tissue-specific regulatory mechanisms. Liver and digestive-system bioregulator research complements Livagen for liver-specific gene regulation and Chonluten for digestive tract bioregulatory studies within the Khavinson peptide framework. As a single defined tripeptide, Ovagen provides research interest in tissue-targeted regulation of the liver and digestive system.

Ovagen research applications extend across multiple areas of digestive system biology including gastric mucosa protection, hepatic metabolic function, gastro-hepatic interactions, digestive enzyme regulation, and coordinated aging processes. Laboratory protocols examine these effects in cell culture systems, tissue explants, and preclinical animal models to understand tissue regulation at molecular and cellular levels.

The peptide’s defined sequence provides reproducible research opportunities for studying coordinated digestive function, protective mechanisms spanning multiple tissues, and system-level regulation. Studies investigate how the bioregulator peptide interacts with both gastric epithelial cells and hepatocytes, the mechanisms underlying tissue-selective effects, and potential applications in understanding integrated digestive system biology.

Molecular Characteristics

Defined Tripeptide:

• Classification: Synthetic peptide bioregulator (Khavinson short peptide)
• Source/Origin: Synthetic (solid-phase peptide synthesis)
• Amino Acid Sequence: Glu-Asp-Leu (EDL)
• Molecular Formula: C₁₅H₂₅N₃O₈
• Molecular Weight: 375.37 Da
• Form: White to off-white lyophilized powder
• Solubility: Water, phosphate buffered saline, cell culture media

Ovagen is a single defined molecular entity. The peptide consists of the tripeptide sequence Glu-Asp-Leu (EDL), produced by solid-phase peptide synthesis to a defined, reproducible composition. This defined structure supports consistent investigation of bioregulatory effects in research models examining coordinated function of the liver and digestive system.

As a short peptide, Glu-Asp-Leu (EDL) belongs to the class of sequences theorized to serve as information molecules, carrying tissue-specific regulatory signals that influence gene expression and cellular function in gastric and hepatic target tissues.

Bioregulator Peptide Research Background

Ovagen belongs to the research category of cytomaxes (bioregulator peptides) with liver and digestive-system targeting. This research approach examines how short peptide signals might coordinate cellular regulation across tissue boundaries. The bioregulator hypothesis proposes that:

1. Functionally related organs may share regulatory peptide signals
2. Short peptide sequences can coordinate function across organ systems
3. These peptides may influence gene expression in multiple related target tissues
4. Bioregulator effects occur through tissue-selective and shared regulatory mechanisms

Research on bioregulators like Ovagen investigates coordinated regulation between gastric and hepatic tissues, examining how peptide signals might modulate integrated digestive function, protective mechanisms, and system-level homeostasis in experimental models.

Research Applications

Gastric Mucosa Research

Ovagen serves as a research tool for investigating gastric epithelial function and protection:

• Gastric Epithelial Cell Studies: Investigation of gastric mucosal cell proliferation, differentiation, and turnover
• Mucosal Barrier Function: Research on gastric mucus production, bicarbonate secretion, and protective barrier integrity
• Acid-Base Regulation: Examination of proton pump expression, parietal cell function, and gastric pH regulation
• Gastric Protective Mechanisms: Studies on prostaglandin synthesis, growth factor expression, and cytoprotective pathways
• Cell Survival Research: Investigation of gastric epithelial cell resistance to acid, pepsin, and oxidative stress

Laboratory protocols employ gastric epithelial cell cultures (AGS, MKN-28, RGM-1), primary gastric cells, and gastric organoid systems to characterize Ovagen effects on gastric mucosal function.

Hepatic Function Research

Research applications extend to liver tissue regulation and metabolism:

• Hepatocyte Metabolic Function: Investigation of glucose metabolism, glycogen storage, and energy homeostasis
• Detoxification Pathway Studies: Research on Phase I and Phase II enzyme expression and xenobiotic metabolism
• Protein Synthesis Regulation: Examination of hepatic protein production including plasma proteins and clotting factors
• Bile Production Research: Studies on bile acid synthesis, conjugation, and transport mechanisms
• Hepatic Regeneration: Investigation of hepatocyte proliferation and liver tissue renewal capacity

Experimental approaches include primary hepatocyte cultures, hepatic cell lines (HepG2, HepaRG), and liver function assays to understand hepatic regulation.

Gastrohepatic Interaction Studies

Laboratory studies investigate Ovagen in coordinated gastric-hepatic function contexts:

• Portal Circulation Research: Examination of gastric-derived signals affecting hepatic function
• Enterohepatic Circulation: Studies on bile acid recycling and gastro-hepatic communication
• Coordinated Metabolism: Investigation of integrated carbohydrate and lipid processing across tissues
• System-Level Protection: Research on coordinated cytoprotective mechanisms in digestive system
• Hormonal Regulation: Examination of gastrin, somatostatin, and other hormones affecting both tissues

Research protocols examine how bioregulator peptides might influence coordinated function between gastric and hepatic tissues through co-culture models and system-level analysis.

Digestive System Aging Research

Ovagen serves as a tool for investigating age-related changes in gastric and hepatic tissues:

• Cellular Senescence Studies: Examination of aging markers in gastric epithelium and hepatocytes
• Gastric Atrophy Research: Investigation of age-related mucosal thinning and reduced secretory capacity
• Hepatic Aging: Studies on declining liver metabolic function and regenerative capacity
• Coordinated Age Changes: Research on simultaneous aging processes across digestive system tissues
• Oxidative Stress Accumulation: Analysis of reactive oxygen species effects in aging gastric and hepatic tissue

Research protocols employ aging models, senescence-associated marker analysis, and comparative studies across different age groups in experimental systems.

Gastric Ulcer and Injury Models

Laboratory studies examine Ovagen effects on gastric injury and repair:

• Ulcer Healing Research: Investigation of mucosal repair mechanisms and epithelial regeneration
• NSAID Injury Models: Studies on gastric damage from non-steroidal anti-inflammatory drugs
• Stress-Induced Damage: Research on restraint stress and cold-induced gastric lesions
• Ethanol Injury Models: Examination of acute gastric mucosal damage and protective mechanisms
• Helicobacter pylori Research: Investigation of bacterial infection effects on gastric epithelium

Experimental models include various gastric injury protocols and mucosal healing assessment systems.

Hepatic Injury and Protection Studies

Ovagen research applications include liver injury model investigation:

• Hepatotoxicity Models: Research on drug-induced, chemical-induced, and toxin-induced liver injury
• Oxidative Stress Research: Examination of reactive oxygen species-mediated hepatic damage
• Inflammatory Liver Models: Studies on cytokine-induced hepatocyte injury and inflammatory pathways
• Steatosis Research: Investigation of lipid accumulation and fatty liver models
• Protective Mechanisms: Analysis of cytoprotective pathways and antioxidant defenses

Research approaches include hepatotoxicity assays, oxidative stress markers, and liver injury biomarkers.

Laboratory Handling and Storage Protocols

Lyophilized Powder Storage:

• Store at 2-8°C (refrigerated) in original sealed vial
• Protect from light exposure and moisture
• Do not freeze lyophilized powder
• Stable for 24 months refrigerated as unopened vial
• Record receipt date for laboratory inventory

Handling Precautions:
Bioregulator peptide preparations require careful handling to maintain activity:

• Use sterile technique for cell culture applications
• Avoid prolonged exposure to room temperature
• Minimize exposure to direct light
• Use appropriate peptide-compatible labware (low-binding tubes)
• Follow standard laboratory peptide handling protocols

Quality Assurance and Analytical Testing

Each Ovagen batch undergoes characterization appropriate for a defined synthetic peptide:

Identity and Purity Analysis:

• High-Performance Liquid Chromatography (HPLC): Purity ≥98%
• Mass spectrometry: Identity confirmed by ESI-MS at 375.37 Da
• Amino acid analysis: Confirms Glu-Asp-Leu (EDL) composition
• Peptide content determination: Quantifies actual peptide content by weight

Purity Testing:

• Peptide purity: HPLC area-percent quantification
• Counterion content: Trifluoroacetate or acetate quantification
• Related substances: Synthesis-related impurities below specified limits
• Heavy metals: Below detection limits per pharmacopeia standards

Contaminant Testing:

• Bacterial endotoxin: <10 EU/mg (LAL method)
• Sterility testing: Sterile filtration and microbiological testing
• Residual solvents: Within acceptable limits
• Water content: Karl Fischer titration (<8%)

Synthesis and Specification:

• Synthetic route: Solid-phase peptide synthesis (SPPS)
• Defined specification: Single Glu-Asp-Leu (EDL) tripeptide, no animal-derived input
• Processing validation: Standardized synthesis and purification protocols
• Batch-to-batch consistency: Quality control testing across production batches

Documentation:

• Certificate of Analysis (COA) with batch-specific data
• HPLC purity chromatogram
• Mass spectrometry identity report
• Quality control test results
• Storage and handling recommendations
• Lot number traceability

Research Considerations

Experimental Design Factors:

Researchers should consider several factors when designing experiments with Ovagen:

1. Concentration Selection: Bioregulator peptide research typically employs concentrations ranging from 0.1-10 μg/mL in cell culture studies. Optimal concentration should be determined empirically for specific experimental systems.

2. Treatment Duration: Published research suggests effects may require 24-72 hours to manifest in cell culture models. Time course studies recommended for new applications.

3. Tissue Specificity: Given the liver and digestive-system targeting, both gastric and hepatic tissue selectivity should be evaluated. Comparative studies with other single-tissue bioregulators may illuminate specific vs. shared effects.

4. Defined-Peptide Considerations: As a single defined tripeptide, effects can be attributed to one molecular entity, simplifying mechanism studies and supporting reproducible interpretation.

5. Model Selection: Consider whether research question requires single tissue type or co-culture/system-level models to capture coordinated effects.

Control Groups:

Appropriate controls for bioregulator peptide research include:

• Vehicle control (vehicle buffer only)
• Single-tissue bioregulators (gastric-only or hepatic-only) for comparison
• Non-specific peptide control (scrambled peptides)
• Positive controls where applicable (growth factors, protective agents)
• Tissue-specific comparisons (same bioregulator concentration in non-target cells)

Mechanism Investigation:

Ovagen mechanisms remain active research areas. Investigated mechanisms include:

• Gene expression modulation in gastric and hepatic cells
• Tissue-selective vs. shared signaling pathway activation
• Growth factor and cytoprotective pathway regulation
• Transcription factor modulation (gastric-specific and hepatic-specific factors)
• Coordinated cellular responses across tissue types
• Epigenetic modifications influencing multiple tissue gene expression

Research approaches combine molecular biology techniques, dual-tissue genomic analysis, comparative proteomic profiling, and functional assays in both cell types to elucidate bioregulator action mechanisms.

Compliance and Safety Information

Regulatory Status:
Ovagen is provided as a research chemical for in-vitro laboratory studies and preclinical research only. This bioregulator peptide has not been approved by the FDA for human therapeutic use, dietary supplementation, or medical applications.

Intended Use:

• In-vitro cell culture research
• Gastric and hepatic tissue explant studies
• In-vivo preclinical research in approved animal models
• Laboratory investigation of gastrohepatic tissue regulation
• Academic and institutional research applications

NOT Intended For:

• Human consumption or administration
• Therapeutic treatment or diagnosis
• Dietary supplementation
• Veterinary therapeutic applications without appropriate oversight
• Any medical or clinical applications

Safety Protocols:
Researchers should follow standard laboratory safety practices:

• Use appropriate personal protective equipment (lab coat, gloves, safety glasses)
• Handle in biosafety cabinet for sterile work
• Follow institutional biosafety guidelines
• Dispose of waste according to biological waste protocols
• Consult material safety data sheet (MSDS) for additional information

Synthetic Origin:
Ovagen is a fully synthetic peptide produced by solid-phase peptide synthesis, with no animal-derived source material. Researchers should:

• Follow institutional research-chemical handling guidelines
• Maintain records of batch certification
• Reference the Certificate of Analysis for identity and purity
• Apply appropriate biosafety level for synthetic peptide reagents

—